NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) - Total Liabilities
Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has total liabilities worth $58.36 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore NewAmsterdam Pharma Company N.V. Ordinar long-term investment allocation to see how much of total assets are deployed in long-term investments.
NewAmsterdam Pharma Company N.V. Ordinary Shares - Total Liabilities Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is NewAmsterdam Pharma Company N.V. Ordinar's balance sheet.
NewAmsterdam Pharma Company N.V. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of NewAmsterdam Pharma Company N.V. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Newell Brands Inc
NASDAQ:NWL
|
USA | $8.61 Billion |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
China | CN¥7.41 Billion |
|
Central Puerto S.A.
BA:CEPU
|
Argentina | AR$1.25 Trillion |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
USA | $396.88 Million |
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
USA | $319.19 Million |
|
Bure Equity AB
ST:BURE
|
Sweden | Skr19.00 Million |
|
Maple Leaf Foods Inc.
TO:MFI
|
Canada | CA$2.81 Billion |
|
Proximus NV
BR:PROX
|
Belgium | €8.79 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down NewAmsterdam Pharma Company N.V. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See NewAmsterdam Pharma Company N.V. Ordinar balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NewAmsterdam Pharma Company N.V. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
The table below shows the annual total liabilities of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $107.12 Million | +82.47% |
| 2023-12-31 | $58.70 Million | +21.21% |
| 2022-12-31 | $48.43 Million | +326.24% |
| 2021-12-31 | $11.36 Million | -8.42% |
| 2020-12-31 | $12.41 Million | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more